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B-cell non-Hodgkin lymphomas �NHL� mostly pres-
ent as disseminated diseases involving lymph nodes� 
spleen and liver and often the �one marrow �BM�. 
Tumor cells can also �e found in the �lood �leukemic 
disease�� especially in the indolent lymphomas. High 
white �lood cell counts and a differential demonstra-
ting a lymphocytosis in the �lood require immunophe-
notyping for characterization of the leukemic cells. 
Molecular/cytogenetic analyses may also have a role 
in the diagnostic classification of the disease. Besides 
the specific diagnosis� the clinical evaluation of the pa-
tient and prognostic markers are of most importance 
for selecting the �est type of therapy.
Follicular lymphoma (FL) is the indolent lymphoma 
with the highest incidence. Most patients present 
with advanced stage disease with BM involvement 
in �����% of the cases� and few are leukemic at the 
time of diagnosis. By high-resolution analysis circulating 
FL cells may �e detected in more patients. Leukemic pa-
tients mostly have concomitant lymph node involvement 
and high tumor �urden. A pure FL-cell leukemia with 
C���+C���+C�5� clonal cells has also �een descri�ed� 
mostly associated with an indolent clinical outcome. 
FL carry a t�l�;l���q��;q�l� translocation in more than 
9�% of cases� juxtaposing the immunoglo�ulin heavy 
chain �IGH� �’ Regulatory Regions �lgH-�’RR� to the 
BCL2 gene� resulting in overexpression of the Bcl� anti-
apoptotic protein. FL cells are also dependent on signals 
from the microenvironment to survive and proliferate. 
Several groups� including ours� have reported that 
immune cells in the lymphoma microenvironment and 
in �lood influence prognosis. In patients treated �efore 
the introduction of rituxima�� we have found that a high 
num�er of P�-�+� FOXP�+ and C��+ T-cell su�sets in the 
tumor microenvironment predict superior outcome� 
while C��+ follicular helper T cells and C�6�+ macro-
phages are associated with an inferior outcome. The 
introduction of the anti-C��� anti�ody rituxima� has 
improved the prognosis for FL patients. The efficacy 
of this drug is excellent also as monotherapy especially 
in patients with high num�ers of C��+ T-cells in the 
lymph nodes as well as in the �lood.
Mantle cell lymphoma (MCL): MCL cells carries 
the t�l �:��� translocation resulting in enhanced cyclin 
�l expression and cyclin �I-dependent kinase activ-
ity� promoting cell cycle progression. Immunological 
markers show a typical phenotype �C���+C�5+C������ 
�ut also atypical phenotypes �C���+C�5�C���� 
or C���+C�5+C���+� in some cases. Most MCL patients 
have an unfavora�le prognosis and intensive treatment 
strategies are required. However� in around ��% of the 
patients the disease shows an indolent clinical course 
with often a non-nodal� leukemic disease. In one study 
the clinicopathologic features� gene expression and 
genomic profiles were compared in patients with in-
dolent �iMCL� and in those with conventional disease 
�cMCL�. iMCL and cMCL shared a common gene 
expression profile that differed from other leukemic 
lymphoid neoplasms and a signature of �� genes was 
underexpressed in iMCL� among these SOXI1. The SOX 
I1-negative tumors exhi�ited more frequent non-nodal 
presentation and �etter survival compared with SOX 
I1-positive MCL. Recently� our group found that SOXII-
negative MCL had a higher frequency of lymphocytosis� 
�ut also elevated L�H and p5� positivity. Moreover� 
SOXII- negative cases had a shorter overall survival than 
SOXII-positive cases. �ue to the conflicting results� the 
conclusion is that SOXII cannot �e used for predicting 
an indolent disease course. In another study� deletions 
at ��p�� (TP53) and ��q�� were frequent in leukemic 
MCL and involved the majority of the leukemic clone. 
Cases with TP53 deletion were more likely to have 
splenomegaly and marked leucocytosis �> �� × ��9/L�� 
and were less likely to have lymphadenopathy than 
those without the deletion. Other distinctive �iological 
features in non-nodal leukemic MCL are mutated IGHV 
and a transcriptional profile lacking tumor invasion prop-
erties� which might contri�ute to the a�sence of nodal 
involvement. In conclusion� MCL patients with leukemic 
disease �ut without clinical symptoms might �e man-
aged conservatively with a “wait and watch” policy� while 
�lastoid morphology� high proliferation and TP53 a�er-
rations are markers of aggressive disease� which will 
require intensive immunochemotherapy.
Marginal zone lymphoma (MZL): There are three 
clinicopathological entities of MZL� including extranod-
al� mucosa-associated lymphoid tissue �MALT� lympho-
ma� nodal �NMZL�� and splenic �SMZL� type. Leukemic 
presentation is more common in SMZL. The leukemic 
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lymphocytes are usually small or morphologically “vil-
lous”� and the leukemic manifestation of SMZL is named 
splenic lymphoma with villous lymphocytes �SLVL�. The 
typical immunophenotype is C��9+C���+C���+C��5+ 
and the clone is often also C� ���+ and C���+. More-
over� C���c is highly associated with SMZL. The genet-
ics and pathogenesis of SMZL are poorly understood 
and specific prognostic features are lacking. A�errant 
karyotypes are seen as gains of �/�q and ��q� deletions 
of �q and 6q and translocations involving �q/�q/l�q. 
Trisomy � and deletions of chromosome �q��-�� are 
most common and found in approximately �5 and �5% 
of cases� respectively. A strong association has �een 
descri�ed �etween usage of the IGVH�-� and deletion 
�q and ��q alterations. Clinical and epidemiological 
data suggest that chronic hepatitis C virus �HCV� infec-
tion may have an etiological role in a su�set of cases. 
MicroRNA �miR�-�6�� a miRNA known to have tumor 
suppressive properties� has �een shown to �e down-
regulated in HCV positive cases. Recent data suggest 
that certain SMZL su�types could derive from progeni-
tor populations adapted to particular antigenic chal-
lenges through selection of VH domain specificities� 
in particular the IGHV �-��*��� allele.
The anti-C��� anti�ody rituxima� is mostly ef-
fective in MZL patients as monotherapy� �ut for many 
patients with symptomatic splenomegaly� splenectomy 
is still a therapeutic option.
In summary� the presence of lymphocytosis in the 
�lood in patients with a suspicion of lymphoma requires 
careful evaluation for the presence of neoplastic lym-
phocytes� especially in the a�sence of easily acces-
si�le enlarged lymph nodes. The differential diagnosis 
�etween the WHO defined mature B-cell malignancies 
has improved �y using multiple-color flow cytometry 
of phenotypic data of the lymphoma cells. This method 
is also of value for characterization of the immune 
cells in the microenvironment and �lood. Molecular/
cytogenetic analyses have a role in classification 
of the disease and for understanding of pathogenesis. 
Therapeutic decisions are always dependant on the 
specific diagnosis� prognostic factors and a careful 
clinical evaluation of the patient.
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Epidemiology and classification
Primary gastrointestinal lymphomas comprise less 
than 5% of all lymphomas diagnosed in the western 
world� with a varia�le geographical and ethnic inci-
dence. The �iology and management vary with the 
main diagnostic �WHO� su�types which include Gastric 
MALT lymphomas� Enteropathy associated T-cell lym-
phoma �EATCL�. Other lymphomas which frequently 
involve the gastrointestinal tract include diffuse large 
B-cell lymphoma� mantle cell lymphoma and Burkitts 
lymphoma; �ut are not considered primary gut lym-
phomas and will not �e covered in this lecture. The 
pathogenesis of MALT and EATCL lymphomas is linked 
to a�normal antigen drive �gluten/Helicobacter infec-
tion� resulting in chronic inflammation and lymphoma 
development. The lymphomas are otherwise radically 
different; MALT lymphomas are indolent B-NHL� which 
respond to antigen-drive withdrawal and minimal 
therapy with an overall survival �OS� > ��% at 5 years� 
whereas EATCL is an aggressive T-cell lymphomas 
associated with a poor outcome.
Gastric MALT lymphoma
Clinical features: Gastric MALT lymphomas in-
cidence in the Western World is approximately 6 per 
